Different affinity of nuclear factor‐kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer

• Published in: The FEBS journal Vol. 281; no. 5; pp. 1393 - 1408
• Main Authors: Kasparkova, Jana, Thibault, Thomas, Kostrhunova, Hana, Stepankova, Jana, Vojtiskova, Marie, Muchova, Tereza, Midoux, Patrick, Malinge, Jean‐Marc, Brabec, Viktor
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.03.2014; Wiley
• Subjects: Adducts; Affinity; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic drugs; Antitumor activity; Apoptosis; Base Sequence; Benzene; Binding; Binding Sites - genetics; Cancer; Cell death; Cell Line, Tumor; Cellular biology; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Cisplatin - chemistry; Cisplatin - pharmacology; Consensus Sequence; Conserved sequence; Cytotoxicity; Deoxyribonucleic acid; Diamines; DNA; DNA adducts; DNA Adducts - chemistry; DNA Adducts - genetics; DNA Adducts - metabolism; DNA, Neoplasm - chemistry; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Drug Synergism; Female; HEK293 Cells; Humans; Life Sciences; modified‐oligodeoxynucleotide decoy strategy; NF-kappa B - antagonists & inhibitors; NF-kappa B - chemistry; NF-kappa B - metabolism; NF‐кB; Nucleic Acid Conformation; Nucleotide sequence; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Pharmacology; Phenylenediamines - administration & dosage; Phenylenediamines - pharmacology; Platinum; Proteins; Stereoisomerism; Toxicity; Transcription factors; Tumor cells; Tumors; NF-кB; modified-oligodeoxynucleotide decoy strategy; cisplatin; antitumor activity; DNA
• ISSN: 1742-464X; 1742-4658
• DOI: 10.1111/febs.12711

Nuclear factor‐kappa B (NF‐кB) comprises a family of protein transcription factors that have a regulatory function in numerous cellular processes and are implicated in the cancer cell response to antineoplastic drugs, including cisplatin. We characterized the effects of DNA adducts of cisplatin and ineffective transplatin on the affinity of NF‐кB proteins to their consensus DNA sequence (кB site). Although the кB site–NF‐κB protein interaction was significantly perturbed by DNA adducts of cisplatin, transplatin adducts were markedly less effective both in cell‐free media and in cellulo using a decoy strategy derivatized‐approach. Moreover, NF‐κB inhibitor JSH‐23 [4‐methyl‐N¹‐(3‐phenylpropyl)benzene‐1,2‐diamine] augmented cisplatin cytotoxicity in ovarian cancer cells and the data showed strong synergy with JSH‐23 for cisplatin. The distinctive structural features of DNA adducts of the two platinum complexes suggest a unique role for conformational distortions induced in DNA by the adducts of cisplatin with respect to inhibition of the binding of NF‐кB to the platinated кB sites. Because thousands of κB sites are present in the DNA, the mechanisms underlying the antitumor efficiency of cisplatin in some tumor cells may involve downstream processes after inhibition of the binding of NF‐κB to κB site(s) by DNA adducts of cisplatin, including enhanced programmed cell death in response to drug treatment. NF‐κB transcription factors have a regulatory function in numerous cellular processes and are implicated in cancer cell response to antineoplastic drugs including cisplatin. The results of this study show that mechanisms underlying antitumor efficiency of cisplatin may involve downstream processes following inhibition of the binding of NF‐κB to κB site(s) by DNA adducts of cisplatin.